{"created_at": "2022-04-29T17:24:40.000Z", "author_id": "1447274377997815808", "text": "RT @unusual_whales: Earnings today!\n\nPre-market:\n$XOM\n$CVX\n$ABBV\n$AZN\n$BMY\n$HON\n$CHTR\n$CL\n$AON\n$TRP\n$PSX\n$WIT\n$LYB\n$IMO\n$WY\n$MGA\n$CBOE\n$NWL\u2026", "id": "1520091709744459776"}
{"author_id": "1486684478688972808", "id": "1520109518876778498", "created_at": "2022-04-29T18:35:26.000Z", "text": "Only 1 buy for me today \n\n$ABBV @ 142.25\n\n$ABBV is down 8.5% after BEATING earnings\n\nEasy add for me in this \u201csell the earnings\u201d environment"}
{"text": "AbbVie $ABBV Reports First-Quarter 2022 Financial Results https://t.co/hsv5t8payP", "author_id": "3142088601", "id": "1520007604541480960", "created_at": "2022-04-29T11:50:27.000Z"}
{"created_at": "2022-04-29T17:42:19.000Z", "author_id": "733717446", "text": "RT @ByAmyBrown: On earnings call $ABBV confirms existing CF triple therapy has been abandoned, but a new triple combo will enter ph2 trials\u2026", "id": "1520096152321888256"}
{"text": "$ABBV | AbbVie Q1 22 Earnings:  \n- Revenue: $13.54B (exp $13.63B)  \n- Adj EPS: $3.16 (exp $3.14)  \n- Sees 2022 Adj EPS $13.92-$14.12", "id": "1520024897250017284", "author_id": "2166486516", "created_at": "2022-04-29T12:59:10.000Z"}
{"author_id": "112872946", "id": "1520112127708696579", "created_at": "2022-04-29T18:45:48.000Z", "text": "$ABBV RINVOQ (upadacitinib) Approved by FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis"}
{"text": "\u30a2\u30c3\u30f4\u30a3 $ABBV 1Q\u6c7a\u7b97\n\n\u274c \u58f2\u4e0a\u9ad8 $13.538B\uff08\u4e88\u60f3 $13.61B\uff09\n\u2319 YoY +4.1%\n\u2b55\ufe0f EPS $3.16\uff08\u4e88\u60f3 $3.14\uff09\n\u2319 YoY +9.3%\n\n\ud83d\udcc9 \u6642\u9593\u5916 -4.31%\n\n\u25b6\ufe0f FY22\u30ac\u30a4\u30c0\u30f3\u30b9\nEPS $13.92 ~ $14.12 (\u4e88\u60f3 $14.11)", "id": "1520016644810047488", "author_id": "1380149678495334405", "created_at": "2022-04-29T12:26:23.000Z"}
{"author_id": "238080130", "id": "1520043031533076480", "created_at": "2022-04-29T14:11:14.000Z", "text": "RT @DividendWave: $ABBV somewhat weak Q1 &amp; lower FY adj. guidance\nRevenue +4.1%\n \u2022Humira -2.2%\n \u2022Humira 35% of revenue\n \u2022Aesthetics +20%\nNe\u2026"}
{"author_id": "1380149678495334405", "id": "1520169409536438272", "created_at": "2022-04-29T22:33:25.000Z", "text": "RT @LOBBSBY: $ABBV \u5916\u3057\u305f\u304b\n\n\u8a73\u7d30\u306f\u5f8c\u3067\u898b\u308b\n\u30dd\u30b8\u30b7\u30e7\u30f3\u306f\u6e1b\u3089\u3057 $JNJ \u306b\u5bc4\u305b\u3066\u3044\u308b\u304c\u30db\u30f3\u5c11\u3057\u524d\u307e\u3067\u7d50\u69cb\u4e16\u8a71\u306b\u306a\u3063\u305f\ud83d\ude0e\n\n$XOM \u3082\u5916\u3057\u305f\u304c\u8a31\u3055\u308c\u305d\u3046\ud83d\ude39"}
{"text": "$ABBV  new alert at https://t.co/A7qrDarJHY  #stocks #daytrading  #NYSE #NASDAQ #market 286", "id": "1520008924937830400", "author_id": "39546678", "created_at": "2022-04-29T11:55:42.000Z"}
{"author_id": "1503287765965828098", "id": "1520111346935017472", "created_at": "2022-04-29T18:42:42.000Z", "text": "$ABBV All that you need to know;. Shorts haven't covered a single share .. https://t.co/y4NIBDm0gi"}
{"author_id": "1259215707817955328", "id": "1520147480695873536", "created_at": "2022-04-29T21:06:17.000Z", "text": "DailyDown5\n$ABBV $146.71 -6.14% -5.34% -9.54% 10.23% 33.46\n$AFRM $28.82 -7.66% -7.51% -40.15% -47.14% 34.27\n$AIRC $49.17 -5.13% -9.13% -10.62% -4.60% 34.94\n$AMZN $2479.50 -14.26% -14.11% -26.78% -11.44% 29.21\n$BBBY $13.69 -7.19% -21.59% -49.72% -9.04% 28.44"}
{"author_id": "225508815", "id": "1520140146276020224", "created_at": "2022-04-29T20:37:08.000Z", "text": "RT @JesseCohenInv: Happy Friday!\n\n*Here Are My #Top5ThingsToKnowToday:\n\n- Stocks Set For Lower Open\n- Nasdaq Futures Drop 1.3%\n- $AMZN Sink\u2026"}
{"text": "$ABBV (-4.4% pre) AbbVie's stock is down 3% after missing on revenue in the first quarter of 2022\n\nhttps://t.co/FcEGdwF7YY", "id": "1520017063007371268", "author_id": "2334614718", "created_at": "2022-04-29T12:28:03.000Z"}
{"author_id": "1351219428969607172", "id": "1520040938055376896", "created_at": "2022-04-29T14:02:55.000Z", "text": "$ABBV -10% pero Mr. Market pro favor...\ud83d\ude33 he ampliado aunque mi precio medio sea muy inferior, cuesta ampliar por encima de tu precio pero sinceramente creo que es excesivo ese -10% y $ABBV es mis empresas favoritas para el largo plazo. Long $ABBV"}
{"created_at": "2022-04-29T16:30:42.000Z", "author_id": "1274949853479604224", "text": "Unusual Volume:\n\n$AAL:  22-05-20 $19.5 C \nLast:$1.0 Vol: 4,639\n\n$AAPL:  22-04-29 $165.0 C \nLast:$0.18 Vol: 89,448\n\n$ABBV:  22-04-29 $150.0 P \nLast:$7.32 Vol: 6,044\n\n$ABNB:  22-04-29 $160.0 P \nLast:$0.9 Vol: 1,056\n\n$AMC:  22-06-17 $14.0 P \nLast:$2.18 Vol: 2,505", "id": "1520078131188666368"}
